{"id":"varinecline-chantix","safety":{"commonSideEffects":[{"rate":"30","effect":"Nausea"},{"rate":"20","effect":"Insomnia"},{"rate":"13","effect":"Abnormal dreams"},{"rate":"13","effect":"Headache"},{"rate":"10","effect":"Dizziness"},{"rate":"8","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL1076903","moleculeType":"Small molecule","molecularWeight":"211.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Varenicline binds with high affinity and selectivity to the alpha-4 beta-2 nicotinic receptor in the brain. As a partial agonist, it provides modest dopamine release to reduce withdrawal symptoms while simultaneously blocking nicotine from binding to these receptors, preventing the reinforcing effects of smoking and reducing the urge to smoke.","oneSentence":"Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:48.072Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation"}]},"trialDetails":[{"nctId":"NCT02575183","phase":"PHASE4","title":"Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2016-08-31","conditions":"Nicotine Dependence","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":102,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Varinecline (Chantix)","genericName":"Varinecline (Chantix)","companyName":"American University of Beirut Medical Center","companyId":"american-university-of-beirut-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Varinecline (Chantix) is a small molecule partial agonist that targets the neuronal acetylcholine receptor, specifically the alpha4/beta2 subtype. It is used to treat nicotine dependence, as indicated by clinical trials for smoking cessation, including waterpipe smoking.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}